Showing 1601-1610 of 2322 results for "".
- Exosome News: ExoCoBio Completes Acquisition of Benevhttps://practicaldermatology.com/news/exosome-news-exocobio-completes-acquisition-of-benev/2461855/ExoCoBio has acquired a majority ownership in BENEV, a global medical aesthetic company that produces growth factor-based skincare products. ExoCoBio produces exosome-based regenerative aesthetics and medicine products and currently holds 54 patents and 15 scientific publicati
- AD Pipeline Watch: Eblasakimab Monthly Dosing Shows Promise in Phase 2b AD Studyhttps://practicaldermatology.com/news/eblasakimab-monthly-dosing-shows-promise-in-phase-2b-ad-study/2461845/ASLAN Pharmaceuticals’ eblasakimab met the primary endpoint of percent change from baseline in the Eczema Area and Severity Index (EASI) score at week 16 versus placebo in adult patients with moderate-to-severe atopic dermatitis (AD), according to results from the Phase 2b dose-ra
- RVL Launches New Prescription E-commerce Platformhttps://practicaldermatology.com/news/rvl-launches-new-prescription-e-commerce-platform/2461844/RVL Pharmaceuticals is launching a prescription e-commerce platform. ELEVATE is a secure subscription platform that allows both providers and patients to purchase RVL products. The platform comprises RVL-initiated auto refills and unlocks ad
- Nemolizumab Monotherapy Curbs Itch in Prurigo Nodularis by Week 4https://practicaldermatology.com/news/nemolizumab-monotherapy-curbs-itch-in-prurigo-nodularis-by-week-4/2461840/Nemolizumab monotherapy quickly tames itch in Prurigo Nodularis, according to a late-breaking late-breaking Phase III study presented at the 25th World Congress of Dermatology (WCD) in Singapore. Fully 19.7% of patients treated with nemolizumab monotherapy achieved an itc
- Dermatology Around the Globe: First JAK for AD Approved in Indiahttps://practicaldermatology.com/news/dermatology-around-the-globe-first-jak-for-ad-approved-in-india/2461828/Intas Pharmaceuticals Ltd launched TOFATAS –a Drugs Controller General of India (DCGI) -approved, Tofacitinib Ointment 2% w/w for the treatment of mild to moderate Atopic Dermatitis (AD) in patients 18 years and above experiencing flare-ups of the disease. "The
- Open Enrollment Underway for Phase 2b Trial of Topical AMTX-100 CF3 in ADhttps://practicaldermatology.com/news/open-enrollment-underway-for-phase-2b-trial-of-topical-amtx-100-cf3-in-ad/2461827/Amytrx Therapeutics is enrolling mild to moderate atopic dermatitis patients for its Phase 2b clinical trial of a topical formulation of AMTX-100 CF3. Eligible adults interested in participating or learning more about the trial are encouraged to visit the
- Oro Health, Dermago Unveil Consumer Version of its AI-powered Dermatology Assessment and Recommendation Toolhttps://practicaldermatology.com/news/oro-health-dermago-unveil-consumer-version-of-its-ai-powered-dermatology-assessment-and-recommendation-tool/2461822/Oro Health and Dermago are unveiling the public version of DermSmart, a tool designed to classify skin types and minor skin conditions. This new AI-driven version offers patients the ability to upload pictures of their skin condition, ask questions and interact with the tool i
- National Rosacea Society Offers New Seal of Acceptancehttps://practicaldermatology.com/news/national-rosacea-society-offers-new-seal-of-acceptance/2461801/The National Rosacea Society is launching a Seal of Acceptance program to identify skin care and cosmetic products that may be suitable for people with rosacea. “One of the most common requests the Society receives from rosacea patients is for info
- Study: Minimal Systemic Absorption of Isotretinoin Seen in Congenital Ichthyosishttps://practicaldermatology.com/news/study-minimal-systemic-absorption-of-isotretinoin-seen-in-congenital-ichthyosis/2461793/Interim pharmacokinetic (PK) analyses from the Phase 3 ASCEND study suggest minimal systemic absorption of isotretinoin or its major metabolites in patients with moderate to severe forms of congenital ichthyosis (CI) who were treated with TMB-001 0.05% ointment, Timber Pharmaceuticals, Inc. repor
- Health Canada Greenlights Sun Pharma’s Winlevi for Acnehttps://practicaldermatology.com/news/health-canada-greenlights-sun-pharmas-winlevi-for-acne/2461792/Health Canada has given its nod to Sun Pharma’s Winlevi (clascoterone cream 1%). Winlevi an androgen receptor inhibitor indicated for the topical treatment of acne vulgaris in patients 12 years of age and older. It will be available in Canada this Fall. "